-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

Benzinga·10/05/2026 12:57:07
Listen to the news
Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.